Mirum Pharmaceuticals (MIRM) Equity Average (2019 - 2026)

Mirum Pharmaceuticals' Equity Average history runs 8 years deep, the most recent figure standing at $278.6 million for Q1 2026.

• In Q1 2026, Equity Average rose 21.42% year-over-year to $278.6 million; the TTM figure through Mar 2026 stood at $278.6 million (up 21.42% YoY), while the FY2025 annual figure was $270.2 million, up 13.92% from the prior year.
• Equity Average was $278.6 million for Q1 2026 at Mirum Pharmaceuticals, down from $303.4 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $303.4 million in Q4 2025 to a low of $109.8 million in Q2 2022.
• Historically, Equity Average has averaged $203.9 million across 5 years, with a median of $229.4 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Equity Average fell 25.11% in 2022, then surged 110.95% in 2024.
• A 5-year view of Equity Average shows it stood at $155.7 million in 2022, then soared by 66.3% to $258.9 million in 2023, then declined by 11.61% to $228.8 million in 2024, then soared by 32.57% to $303.4 million in 2025, then declined by 8.17% to $278.6 million in 2026.
• The last three Equity Average figures came in at $278.6 million (Q1 2026), $303.4 million (Q4 2025), and $273.6 million (Q3 2025), per Business Quant data.